HIV Postexposure Prophylaxis Guidelines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ATLANTA-Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

ATLANTA—Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

Because most occupational HIV exposures do not result in the transmission of HIV, potential toxicity must be carefully considered when prescribing PEP (see Table). Health care personnel with occupational exposure to HIV should receive follow-up counseling, postexposure testing, and medical evaluation, regardless of whether they receive PEP. For management resources, see PEPline (www.ucsf.edu/hivcntr) and Needlestick! (www.needlestick.mednet.ucla.edu).

The basic 2-drug PEP regimens, given for 4 weeks, as recommended in the Table, are zidovudine (Retrovir)/lamivudine (Epivir) (available as Combivir); lamivudine/stavudine (Zerit); and didanosine (Videx)/stavudine.

The expanded 3-drug regimen consists of a basic regimen plus indinavir (Crixivan), nelfinavir (Viracept), efavirenz (Sustiva), or abacavir (Ziagen). Abacavir is available in combination with zidovudine and lamivudine as Trizivir.

Drugs for use as PEP with expert consultation include ritonavir (Norvir), saquinavir (Fortovase), amprenavir (Agenerase), delavirdine (Rescriptor), and lopinavir/ritonavir (Kaletra). 

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content